[{Image src='ICARe.png' caption='' width='600' alt='ICARe' align='center'}]
!!International Course on Antibiotics and Resistance (ICARe)
!October 6-14, 2018, Les Pensières, Annecy (France)
[{Image src='Courvalin_Patrice_small.jpg' caption='Patrice Courvalin' height='200' alt='Patrice Courvalin' class='image_left'}]
__Course Director:__ [P. Courvalin|Member/Courvalin_Patrice], MAE, Institut Pasteur\\
__Scientific Advisors:__ M. Gilmore, Harvard Medical School, G. Wright, McMaster University\\
__Scientific Committee:__ C. Arias, K. Bush, G. Challis, T. Dougherty, S. Lahiri, S. Lory, A. Myers,
S. Projan, H.-G. Sahl, M.-W. Tan
\\ \\
__Objective:__ The emergence and spread of bacteria resistant to many drug classes seriously
threaten all branches of modern medicine. There is currently no course providing advanced
instruction on antibiotics and resistance. The specific goal of ICARe is to bring leaders in
academics and industry together with trained scientists at the dawn of their careers. Cuttingedge
approaches for the study of resistance and antibiotic discovery will be examined.
\\ \\
__Course:__ The faculty, composed of 35 internationally recognized scientists and physicians who
have made important contributions to antibiotic development, infectious diseases and
resistance management will be in residence for a minimum of two days for informal
interactions. Graduates will emerge with a state-of-the-art understanding of existing
antibiotics: modes of action, mechanisms of resistance, approaches for mining chemical
space, advancing hits to leads, the application of next generation nucleic acid-based
technologies for antibiotic discovery and resistance detection. The course aims to build an
international cadre of collaborative, well networked, and highly trained specialists.
\\ \\
__Audience:__ ICARe is designed for assistant professors, post-doctoral and ID fellows, new
scientists from diagnostic, pharmaceutical industry, or from biotech, either working in or
contemplating entering the field of antibiotics. Decision-makers involved in the discovery,
development, and approval of new antibiotics, in the elaboration of programs for better use of
antibiotics and reducing the development of resistance. From both the public and private
sectors. Attendance will be limited to 40 students.
\\ \\
__Selection criteria:__ Participants will be selected by the Scientific Committee that will ensure
that the participants reflect the global nature of the problem with a special attention to gender
equality, according to their educational background, involvement in the field of antibiotics
(research projects, scientific or industrial, which could be presented during the course are
welcome), decision-making responsibility in the finding of new antibiotics and of their
appropriate use.
\\ \\
__Format:__ The course will be administered over 8 days and will consist of formal instruction and
hands-on bioinformatics.
\\ \\
__Organizing committee:__ C. Grillot-Courvalin, M. Sala, B. Pansier\\
__Download:__ the [program|ICARe 2018 Outline .pdf] and the [flyer|ICARe_2018_WEB.pdf].
[{Image src='ICARe_2018_WEB.jpg' caption='' height='700' alt='ICARe_2018_WEB.jpg' class='image_right'}]
!!Program outline

__Current Infectious disease management and antibiotic use__\\
The problem of antibiotic resistance in the developed and developing world\\
Evaluation of susceptibility by phenotypic techniques and clinical categorization\\
Biochemistry and genetics of resistance\\
Overview of history and current strategies for antibiotic discovery
\\ \\
__Modes of action and mechanisms of resistance of existing classes__\\
''Cell wall:'' Structure, biosynthesis, targets\\Cationic peptides, polymixins, bacitracin\\
''Outer- and Inner-membrane:'' Structure and function\\
__Ribosome:__ Structure and function\\
Aminoglycosides, Tetracyclines, fusidic acid, chloramphenicol Macrolides-Lincosamides-Streptogramins, pleuromutilins, oxazolidinones\\
''Nucleic acid synthesis, replication, transcription:'' Inhibitors of biosynthesis, quinolones, rifampicin, fidaxomicin
__Efflux:__ structure-function of efflux systems and inhibitors
''Efflux in P. aeruginosa'' and ''A. baumannii''
\\ \\
__Origin, mutations, and identification of resistance mechanisms__\\
Origins of resistance genes\\
Mutations, selection, biological cost, compensation\\
Mobile genetic elements
\\ \\
__Antibiotic discovery__\\
Antibiotic chemical space in Gram-positives and -negatives\\
Antibiotic chemical matter: Natural products\\
Antibiotic chemical matter: Synthetics\\
Target ''vs'' non-target based strategies\\
Screens and hit generation
\\ \\
__Antibiotic development and approval__\\
Hit to lead\\
PK/PD key elements and optimizing leads Preclinical toxicity assessment, compound scale-up Pathways to approval and
\\ \\
__New topics in antibiotic discovery__\\
Systems biology to guide antibiotic discovery and mode of action\\
Antibiotic enhancers and suppressors of resistance
\\ \\
__Strategies for more focused applications of antibiotics__\\
Narrow spectrum antibiotics Targeting virulence, biofilm Targeted delivery\\
Antibody-antibiotic conjugates
\\ \\
__New technologies for determination of susceptibility and detection of resistance__\\
Antibiogram interpretation\\
Rapid techniques and point-of-care\\
Mass spectrometry
\\ \\
__New anti-infective strategies__\\
Antibodies, vaccines, bacteriophages, CRISPR/Cas9
\\ \\
Choosing the DNA sequence technologies\\
Databases for antibiotic resistance and virulence Detection and identification of resistance genes
TnSeq, RNASeq\\
Bioinformatic analysis of outbreaks\\
Functional genomics and phylogeny
!!Provisional core faculty

J. Ambler, Wockhardt Pharmaceuticals, USA\\
D. Andes, University of Wisconsin, USA\\
C. Arias, University of Texas, USA\\
D. Bikard, Institut Pasteur, France\\
E. Brown, McMaster University, Canada\\
K. Bush, Indiana University, USA\\
G. Challis, University of Warwick, UK\\
J.-P. Charrier, bioMérieux, France\\
P. Courvalin, Institut Pasteur, France\\
J.-D. Docquier, University of Siena, Italy\\
T. Dougherty, Harvard Medical School, USA\\
M. Fisher, St George’s University, UK\\
M. Gilmore, Harvard Medical School, USA\\
C. Giske, Karolinska Institutet, Sweden\\
C. Grillot-Courvalin, Institut Pasteur, France\\
R. Hall, University of Sydney, AU\\
L. Hall-Stoodley, Ohio State University, USA\\
D. Hooper, Massachusetts General Hospital, USA\\
D. Hughes, Uppsala University, Sweden\\
S. Lahiri, Macrolide Pharmaceuticals, USA\\
F. Lebreton, Harvard Medical School, USA\\
S. Lory, Harvard Medical School, USA\\
A. Mankin, University of Illinois, USA\\
H. Moser, Novartis, USA\\
A. Myers, Harvard University, USA\\
M. Page, Basel, Switzerland\\
K. Pos, Goethe University, Germany\\
S. Projan, MedImmune, USA\\
M. Pucci, Spero Therapeutics, USA\\
R. Rappuoli, GSK, Italy
D. Rasko, University of Maryland, USA\\
J. Rex, F2G, USA\\
G.-M. Rossolini, University of Siena, Italy\\
H.-G. Sahl, University of Bonn, Germany\\
J. Schrenzel, Geneva University Hospitals, Switzerland\\
M.-W. Tan, Genentech/Roche, USA\\
Y. Taur, Memorial Sloan Kettering Cancer Center, USA\\
M. Trent, University of Georgia, USA\\
T. Walsh, Cardiff University, UK\\
G. Wright, McMaster University, Canada
\\ \\
[{Image src='pasteur2.png' caption='' height='120' alt='Institut Pasteur' class='image_left'}]